DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today its intention, subject to market and other conditions, to offer $80 million of its common stock in a registered public offering pursuant to its existing shelf registration statement. Inspire also intends to grant to the underwriter of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. Inspire plans to use the proceeds from the common stock offering for general corporate purposes. Deutsche Bank Securities Inc. is acting as sole underwriter of the offering.
